Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NYSEAMERICAN:MAIA

MAIA Biotechnology Q3 2026 Earnings Date & Estimates

MAIA Biotechnology logo
$1.12 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.13 +0.01 (+0.89%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MAIA Biotechnology is estimated to report Q3 2026 earnings on Friday, November 6, 2026. The conference call is scheduled for 9:30 AM ET.

Research:ProfileEarnings History

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from MAIA Biotechnology in Q3 2026

MAIA Biotechnology is expected to post earnings of -$0.13 per share. In the same quarter a year earlier MAIA Biotechnology reported -$0.27 per share. MAIA Biotechnology last reported on August 10, 2026, posting -$0.13 per share and missing the -$0.11 consensus estimate. MAIA Biotechnology has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.13
Prior-Year EPS
-$0.27

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.13 (Missed by -$0.02)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

MAIA Biotechnology Q3 2026 Earnings FAQ

MAIA Biotechnology (NYSEAMERICAN:MAIA) is estimated to report Q3 2026 earnings on Friday, November 6, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

MAIA Biotechnology's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect MAIA Biotechnology to post earnings of -$0.13 per share for Q3 2026.

MAIA Biotechnology Earnings Headlines

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%
October 7, 2026  |  rttnews.comhttps://www.rttnews.com/3697278/maia-completes-thio-101-part-c-enrollment-phase-3-enrollment-hits-65.aspx
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376441/0/en/maia-biotechnology-achieves-patient-enrollment-milestones-in-ongoing-phase-2-and-pivotal-phase-3-clinical-trials-in-non-small-cell-lung-cancer.html
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
October 15 at 1:00 AM  |  Investors Alley (Ad)
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Jumps 0.8% - What's Next?
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094271
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372838/0/en/diamond-equity-research-releases-update-note-on-maia-biotechnology-inc-nyse-maia.html
MAIA Biotechnology, Inc. berichtet über Fortschritte in der zulassungsrelevanten Phase-3-Studie bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs
September 23, 2026  |  de.marketscreener.comD
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company’s research is centered on telomere biology, an area that seeks to exploit the mechanisms cancer cells use to maintain their ability to divide and survive.

MAIA’s lead investigational product is atebimetostat, also known as THIO or 6-thio-2’-deoxyguanosine. The small-molecule therapy is designed to induce telomere dysfunction and promote the death of cancer cells. The company has evaluated atebimetostat in clinical studies involving patients with advanced non-small cell lung cancer, including research exploring its use following treatment with immune checkpoint inhibitors and in combination with immunotherapy.

MAIA Biotechnology was founded in 2018 and is headquartered in Chicago, Illinois. The company has been led by co-founder Vladislav Sandler, who serves as chief executive officer. Its development activities are focused primarily on advancing atebimetostat and related telomere-targeting approaches for patients with difficult-to-treat solid tumors.

View MAIA Biotechnology Profile
Earnings Tools